CellSource Co

CellSource Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of CellSource Co (4880.T) as of Oct 27, 2026 is 2.34 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 1.82 % — a change of 28.75% (higher).

EBIT/Assets

2.34 %

YoY

28.75%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of CellSource Co is 2025 2.34 % . Operating Income to Assets Ratio (EBIT/Assets) of CellSource Co was 2024 1.82 % . It decreases by 28.75% higher compared to the previous year.

The CellSource Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
42.34 JPY
Jan 1, 2019
17.66 JPY
Jan 1, 2020
17.67 JPY
Jan 1, 2021
29.51 JPY
Jan 1, 2022
34.15 JPY
Jan 1, 2023
18.32 JPY
Jan 1, 2024
1.82 JPY
Jan 1, 2025
2.34 JPY
The CellSource Co EBIT/Assets history
YEAREBIT/AssetsYoY
2.34 %+28.75%
1.82 %-90.06%
18.32 %-46.35%
34.15 %+15.71%
29.51 %+67.03%
17.67 %+0.05%
17.66 %-58.29%
42.34 %-12.90%
48.61 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Operating Income to Assets Ratio (EBIT/Assets) of CellSource Co is 2.34 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of CellSource Co changed from 1.82 % to 2.34 %, representing a 28.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) CellSource Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s CellSource Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — CellSource Co

All Key Metrics — CellSource Co